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Introduction
As long as 25 years after treatment of primary uveal melan-
oma (UM), metastases are the leading cause of death and,
eventually, over 50% of patients die of metastatic disease
[1,2]. The liver is the first site of metastases in 90% of
patients and remains the only site in more than 50% of
them [2,3]. Thereafter, the median overall survival (OS) has
been 13months with little difference between non-surgical
treatments [4,5]. Neither advances in managing the primary
tumour nor novel therapies for metastatic cutaneous melan-
oma have translated to survival benefit in metastatic UM
[6,7]. In fact, no consensus exists on which first-line treat-
ments for metastatic UM, if any, provide OS benefit.
There is no published survival data on consecutive patients
managed with best supportive care (BSC) to allow historical
comparison with those actively treated, although such data
would be valuable for planning and analysing trials of meta-
static UM, most of which continue to be non-randomised and
non-comparative [8,9]. We report population-based OS accord-
ing to previously validated prognostic stages [10] for patients
with metastatic UM managed only with BSC.
Methods
Study design
Eligible to our retrospective observational cohort study were
patients previously treated for primary UM in the Ocular
Oncology Service, Department of Ophthalmology, Helsinki
University Hospital, Finland, who developed metastases
between January 1999 and December 2016, and received
only BSC, although palliative radiotherapy to control pain
was allowed for five patients [11,12]. The BSC decision was
made by an oncologist in 96% of the patients and by a gen-
eral practitioner in 4%. Our service is a national referral
centre that manages over 95% of Finnish patients with UM.
The institutional review board and the National Institute for
Health and Welfare approved our study.
Data collection
We obtained patient charts from all hospitals managing meta-
static UM. Because the Finnish law permits destroying patient
records 12years after death, data were incomplete for 21
patients. Of 338 patients with metastatic UM, 111 received no
active treatment but two of them were diagnosed only at aut-
opsy and excluded (Supplementary Figure S1).
We adapted definitions of the Collaborative Ocular
Melanoma Study (COMS) [1,13] to ascertain whether meta-
static UM was present, and obtained histopathologic speci-
mens for review (Supplementary Text). Based on that, one
patient was excluded, resulting in 108 enrolled patients.
We recorded the gender, age, date of diagnosis of the pri-
mary and metastases, Tumour, Node, Metastasis (TNM) stage
[14,15], date of treatment decision (i.e. BSC), liver function
tests (LFTs), Eastern Cooperative Oncology Group perform-
ance status (PS) [16], sites of metastases, the largest diameter
of the largest metastasis (LDLM), symptoms, participation in
regular follow-up to detect metastases [17], and the date
and registered cause of death. The regular follow-up
included annual LFTs and upper abdominal ultrasonography
(US), followed by magnetic resonance imaging or computed
tomography when metastases were suspected. Follow-up
ended on December 31, 2018.
Outcomes
Our primary endpoint is OS from the date of treatment deci-
sion to death as most common in clinical trials [4,18]. A sec-
ondary endpoint is OS from the date of diagnosis of
metastases to death that is less frequently reported in the lit-
erature [4].
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In TNM staging, metastatic UM is currently divided in
three categories (M1a to M1c) based on LDLM [14]. The PS
and serum or plasma alkaline phosphatase (AP) level are
additional independent predictors of OS [3,10]. The Helsinki
University Hospital Working Formulation (WF) staging uses
all three variables and has been validated by the European
Ophthalmic Oncology Group (Supplementary Table S1) [10].
We assigned patients to the WF stages IVa, IVb, and IVc [10]
by calculating their individual predicted median OS (online
calculator available at http://www.prognomics.org/huhwf.
aspx). As originally described, the WF stages correspond to
median predicted OS of 12, <12–6, and <6months,
respectively, based on data at the time of diagnosis of meta-
stases. For primary outcome assessment, we used the same
data as available at the time of treatment decision.
The LDLM, PS, or AP level were missing for 16 patients,
preventing calculation, but we could assign the WF stage for
13 of them using a published summary table [3].
Statistical analysis
Analysis was performed with Stata (version 15, Stata Corp.,
College Station, TX). All p-values are two-tailed, and p<.05
was considered significant. We report median with range
and interquartile range (IQR) for continuous variables and
compare gender distribution using binomial test. We esti-
mated OS using Kaplan-Meier product-limit method, report
the median OS with 95% confidence interval (CI), and com-
pare unordered and ordered categories with the log-rank
test and test for trend, respectively.
We used Cox proportional hazards regression to check
whether gender, age at the time of treatment decision (cate-
gorized as <80 and 80, based on the age criterion for
referral to a geriatric oncologist), relapse-free interval (RFI)
(from the primary tumour to the diagnosis of metastases),
symptoms from metastases, LDLM (TNM categories M1a,
<30mm; M1b, 31–80mm; M1c, >80mm) [14], AP level (cate-
gories <1.0 X, 1.0–2.0 X, >2.0 X upper normal limit [UNL]),
and PS (categories 0–1, 2, 3–4 according to the WF) retained
residual predictive power, given the WF stage, and might
thus help predict OS. We allowed independent variables in
models if p<.10, tested the assumption of proportional haz-
ards using scaled adjustment of Schoenfeld residuals [19],
and compared models using the deviance test.
Results
Patient characteristics
The median age of the 108 patients with metastatic UM
managed only with BSC was 78 (range, 48–95) at the time of
treatment decision (Table 1). The median RFI was 32months
(range, 0–194; IQR 2–150; Supplementary Figure S2). The
characteristics of the primary UM are summarised in
Supplementary Table S2.
Ninety-four percent of patients attended regular follow-
up, 41% were asymptomatic, and 94% had liver metastases
with or without other sites of metastases (Table 1). The
median LDLM was 33mm (range, 2–270). The AP exceeded
UNL in 50% of 94 patients with available data. The PS was
0–2 and 3–4 for 44% and 52% of patients, respectively.
The median interval from diagnosis of metastases to treat-
ment decision (i.e. BSC) was 29 days (range, 0–758; IQR,
7.5–63). The median OS after treatment decision was
1.6months (range, 0–83; Figure 1(A)). One patient was alive
with progressive metastases at the time of analysis. The aud-
ited cause of death was metastatic UM for others.
Overall survival by stage
Of the 105 patients who could be staged according to the
WF, 24% represented stage IVa, 19% IVb, and 55% IVc. The
median OS from treatment decision shortened with increas-
ing stage. It was 12 (range, 1.6–83), 5.7 (range, 0.5–40), and
0.6 (range, 0–8.0) months for stage IVa, IVb, and IVc, respect-
ively (p<.001, log-rank test for trend, Figure 1(B)). By univari-
able Cox regression, WF predicted shorter OS: stage IVb
versus IVa (p¼.038, HR 1.9), IVc versus IVb (p<.001, HR 4.2),
and IVc versus IVa (p<.001, HR 11.9; Supplementary
Table S3).
In stage IVa, 50% of patients survived with BSC for
12months (Supplementary Figure S3). In stage IVb, 50%
and 25% of patients survived 6 and 12months, respect-
ively. In stage IVc, 97% of them died within 6months.
The weighted kappa for agreement between observed
and predicted OS category was 0.614 and 0.615 (agreement
84% versus 59% expected, p<.001 and 83% versus 57%
expected, p<.001, Supplementary Table S4), calculated from
the treatment decision and diagnosis of metastases, respect-
ively [10].
The historical benchmarks for OS from treatment decision,
stratified by WF stage, and an Excel file with the correspond-
ing data to calculate the historical survival curve are pro-
vided (Appendix C, D, and https://doi.org/10.5281/
zenodo.3369090).
Verification of and search for further prognosticators
Regarding the components of the WF, the median OS from
treatment decision was 9.7months (range, 0.5–83) for PS
0–1, 6.1months (range, 0.2–40) for PS 2, and 0.6months
(range, 0–27) for PS 3–4 (p<.001, log-rank test for trend). A
higher AP level and a larger LDLM (by TNM M1 category)
also associated with shorter OS (p<.001), verifying their valid-
ity as predictors when analysing OS with BSC.
The median OS was 1.1, 1.0, and 1.9months for RFI <2.0,
2.0–3.5, and >3.5 years, respectively (p¼.033, log-rank test for
trend; Supplementary Figure S4 for different variables); and
8.3months for absence of symptoms from metastases versus
0.6months for presence of symptoms (p<.001, log-rank test).
In bivariable Cox regression models with WF stage, pres-
ence of symptoms independently predicted survival (p<.001),
and this model fitted better with the data (–2 log likelihood
¼ 332.59 versus 348.27, p<.001, df¼ 1; Supplementary
Table S3).
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Stratified by WF stage, none of the other variables was
significant in all three strata of WF stage (Supplementary
Table S5).
Discussion
Our nation-wide study with BSC for metastatic UM shows
that the WF staging, previously validated by the OOG for
mainly actively treated patients [10], differentiates also
patients receiving BSC by OS. The agreement between pre-
dicted and observed OS, evaluated by weighted kappa, was
even stronger in our dataset than in the OOG validation
study (0.388), irrespective of whether we based staging on
data at the time of treatment decision or diagnosis of meta-
stases (0.614 and 0.615, respectively) [10].
Also, to the best of our knowledge, our cohort is the
second largest one of patients receiving BSC for metastatic
UM, and we are the first to stage them. We are aware of
seven previous reports that included 11 to 191 patients with
BSC [9,20–25]. One of these studies also analysed prognostic
factors and found, in line with us, that patients who received
BSC had worse PS than actively treated [23].
Correspondingly, the PS, but also the AP level and LDLM, the
two other components of the WF, were independent predic-
tors of OS in our dataset.
The median OS of 1.6months in our BSC cohort was sub-
stantially shorter than 13months in our recent meta-analysis
of 2,494 actively treated patients and 10months in another
meta-analysis of 921 patients [4,5], but the stage distribution
in the latter studies probably was very different [23]. The WF
stage was available in 3 of 78 studies [26–28] included in the
first meta-analysis, but none of them reported on BSC.
To best match our results with clinical research practice,
we chose as our primary outcome the OS from treatment
decision, as required of trials by the European Medicines
Agency and the U.S. Food and Drug Administration [29,30].
The median interval between diagnosis of metastases and
BSC decision was only 29 days in our cohort, and the agree-
ment with observed OS was equivalent for both of
these endpoints.
The median OS in the OOG validation study was
11months, expectedly much longer than 1.6months with
BSC [10]. However, the median OS for stage IVa and, espe-
cially, stage IVb was more similar — 17 versus 14months
and 10 versus 8.6months, respectively. The vast majority of
patients with PS 0–1 in our study fell in these two stages.
Table 1. Baseline characteristics of 108 patients with metastatic uveal melanoma managed with best supportive care, and stratification by the Helsinki











Female 53 (49) 14 (54) 11 (55) 27 (46)
Male 55 (51) 12 (46) 9 (45) 32 (54)
Age at treatment decision, median (range, IQR), years 78 (48–95, 55–93) 83 (64–95, 72–91) 79 (48–90, 70–85) 77 (48–94, 57–87)
Relapse-free interval, N (%)c
<2.0 years 44 (41) 7 (27) 10 (50) 25 (42)
2.0–3.5 years 27 (25) 7 (27) 4 (20) 16 (27)
>3.5 years 37 (34) 12 (46) 6 (30) 18 (31)
Symptoms from metastasis, N (%)
No 44 (41) 20 (77) 14 (70) 10 (17)
Yes 60 (56) 6 (23) 6 (30) 47 (80)
Unknown 4 (4) 0 (0) 0 (0) 2 (3)
Histologic confirmation, N (%)d
Available 62 (57) 14 (54) 8 (40) 40 (68)
Not available 46 (43) 12 (46) 12 (60) 19 (32)
Location of metastases at the time of diagnosis, N (%)
Liver only 75 (69) 19 (73) 10 (50) 44 (75)
Liver and other sites 27 (25) 6 (23) 8 (40) 13 (22)
Only other sites 6 (6) 1 (4) 2 (10) 2 (3)
TNM M1 category
30mm (M1a) 43 (40) 22 (85) 9 (45) 11 (19)
31–80mm (M1b) 32 (30) 3 (12) 10 (50) 19 (32)
>80mm (M1c) 16 (15) 0 (0) 1 (5) 14 (24)
Unknown 17 (16) 1 (4) 1 (5) 15 (25)
Serum or plasma alkaline phosphatase level, N (%)
<1.0 X UNL 47 (44) 17 (65) 13 (65) 16 (27)
1.0–2.0 X UNL 18 (17) 0 (0) 1 (5) 16 (27)
>2.0 X UNL 29 (27) 1 (4) 4 (20) 24 (41)
Unknown 14 (13) 8 (31) 2 (10) 3 (5)
Performance status, N (%)e
0–1 35 (32) 25 (96) 8 (40) 2 (3)
2 13 (12) 0 (0) 8 (40) 5 (8)
3–4 56 (52) 1 (4) 4 (20) 50 (85)
Unknown 4 (4) 0 (0) 0 (0) 2 (3)
IQR: interquartile range; UNL: upper normal limit.
aStage IVa corresponds to predicted overall survival of 12months, IVb <12–6months, and IVc <6months; three patients could not be staged.
bBinomial test, p¼.51.
cRelapse-free interval is defined as the time from the primary tumour to the diagnosis of metastases.
dPlease see Supplementary Text in Appendix A for details.
eEastern Cooperative Oncology Group performance status.
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These observations are in line with a previous study that
compared OS with systemic chemotherapy and BSC, and
found no difference by multivariate analysis [23]. The OS for
stage IVc in the OOG cohort was 4 times as long, 4.6months
versus 1.1months, as with BSC [10]. Of our patients with
stage IVc, 85% had a poor PS and they were thus probably
excluded from active systemic treatment unlike in the
OOG study.
Our overall and WF stage-specific benchmarks remain pro-
visional until verified and refined with independent datasets.
Limitations of our study include, in addition to the retro-
spective data collection, lack of genetic prognosticators and
lack of a universal definition of BSC [12]. To improve under-
standing of the natural course of metastatic UM, we encour-
age collaboration to enrol patients who receive BSC in order
to collect their WF stage and additional prognostic factors,
especially genetic ones [31–33]. We strongly advocate using
a validated system, such as the WF stage, for evidence-based,
stage-specific reporting of outcomes.
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